Amicus Therapeutics Inc
FOLD
Get informed when a big investor buys or sells
+ FollowCurrent Fair Value
12.9% downsideOvervalued by 12.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $4.55 Billion |
|---|---|
| Enterprise Value | $4.78 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.09 |
| Beta | 0.48 |
| Outstanding Shares | 309,028,669 |
Return
| Return on Equity | -9.89% |
|---|---|
| Return on Assets | -2.85% |
| Return on Invested Capital | -4.06% |
Valuation & Multiples
| P/E Ratio | -165.17 |
|---|---|
| PEG | 186.56 |
| Price to Sales | 7.25 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 7.53 |
| Enterprise Value to EBIT | -165.46 |
| Enterprise Value to Net Income | -177 |
| Total Debt to Enterprise | 0.09 |
| Debt to Equity | 1.61 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.6882▼ 117.30% |
|---|---|
| Total Calls | 615,100▼ 26.53% |
| Total Puts | 423,300▼ 72.83% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 107.37%▲ 3.27% |
|---|---|
| Total Invested | $4.79B▲ 4.90% |
| Investors Holding | 307▼ 44.00% |
ESG Score
No data
About Amicus Therapeutics Inc
CEO: John Crowley Relevant Senate Committees
Provides official revenue estimates and technical expertise for all tax bills, directly influencing corporate tax structures and capital investment credits essential for a pharmaceutical company's financial planning and R&D.
Controls taxation (corporate valuations), trade policy (supply chains), and entitlement spending (Medicare pricing), all of which significantly impact pharmaceutical companies.
Allocates federal spending, including crucial funds for health-related agencies (FDA, NIH) and healthcare programs, directly impacting the pharmaceutical sector's regulatory environment and funding opportunities.
Directly regulates the FDA and NIH, which are crucial for drug approval processes, research funding, and overall oversight of the pharmaceutical and biotech sectors.
Critical for intellectual property (patent protection) and antitrust enforcement, which are fundamental to the business model and market structure of pharmaceutical companies.